With over 400 million persistent sufferers, India is without doubt one of the world’s largest drugs markets. However whereas most e-pharmacies chase pace, affordability stays the true problem. Truemeds took a unique route: serving to sufferers swap to lower-cost substitutes, a wager now paying off with new funding at about 4 occasions its earlier valuation.
The six-year-old startup has raised $85 million in a brand new spherical that features $65 million in main and $20 million in secondary funding led by Accel, together with participation from Peak XV Companions. TechCrunch first reported on Accel’s talks to again Truemeds final 12 months. Current buyers WestBridge Capital and InfoEdge Ventures, additionally participated.
The contemporary spherical has boosted Truemeds’ valuation to over $400 million, up from the $110 million in its final spherical two years in the past.
Based in 2019, Truemeds entered the market at a time when India’s on-line pharmacy area was already crowded with main gamers providing steep reductions on branded generics. However a few of these firms struggled to maintain early momentum — Prosus Ventures-backed PharmEasy, as an illustration, noticed its valuation drop from a peak of $5.6 billion to below $600 million, whereas 1mg was acquired by Tata Digital, a part of the Tata Group. As a substitute of competing head-on, Truemeds’ founders selected to concentrate on a comparatively area of interest section: generic medicines.
“There isn’t a option to educate the consumer that you would be able to have extra reasonably priced choices if you happen to can’t afford these medication,” mentioned Truemeds co-founder Akshat Nayyar (pictured above, left) in an interview. “That’s the place we felt that no person within the worth chain was working in the direction of that, and we will bridge that hole.”
The Mumbai-based outfit recommends generic alternate options to customers for the branded medicines they want. This ultimately helps customers get monetary savings, as generic medication are usually extra reasonably priced than their branded variations as a consequence of value efficiencies of their improvement course of.
Truemeds says its differentiated method has paid off, with income rising over 66% year-over-year to ₹5 billion ($57 million) within the final monetary 12 months. The startup says it retains greater than 50% of its income after 12 months and now serves a mean of 500,000 prospects every month, with a complete of three million prospects to this point. Furthermore, it says it now serves over 20,000 postal codes throughout the nation, with greater than 75% of its prospects coming from tier-2 cities and past.
Techcrunch occasion
San Francisco
|
October 27-29, 2025
Nevertheless, educating prospects about alternate options to their prescribed medicines — and convincing them to modify from branded medication to generics — stays a problem.
“Since you get anchored to your prescribed model’s worth, and once you abruptly see a lower cost, you need to know why it’s low,” Nayyar informed TechCrunch.
Growing reductions whereas opponents in the reduction of
Whereas at present’s e-pharmacies chase pace over financial savings, the sector’s early playbook was completely different. On-line pharmacies in India used to supply reductions of as much as 25% to draw prospects. However Nayyar mentioned this dropped to twenty% after which 15% — the brand new common — as most burned money to accumulate new prospects and pivoted to quicker supply as their foremost differentiator.
Truemeds has gone in the wrong way, rising its common reductions from 29% to 32% within the final 12 months. For a mean consumer who switches manufacturers on the platform, financial savings attain 47% on their drugs, says the corporate.
This comes from Truemeds’ deep procurement relationships with pharma firms, the place the startup makes use of its know-how to provide producers higher demand visibility, serving to them plan manufacturing extra effectively for upcoming quarters, he mentioned.
The startup additionally depends by itself logistics in among the main cities it operates in and makes use of low-cost logistics companions for the remaining.
“We consider that our four-hour supply mannequin is greater than enough from a persistent affected person’s perspective,” mentioned Nayyar. “You’re capable of do extra deliberate purchases that manner, however we need to do it in essentially the most environment friendly method, and move increasingly reductions to the top consumer slightly than [focus on] the quickest supply for that matter.”
Subsequent up: AI-powered customization and doorstep diagnostics
As Truemeds must persuade prospects to decide on generics over branded medicines, it goes by way of deeper consultations with them. It already conducts 10-12 million consultations per 12 months. The startup has developed an algorithm over time that appears at numerous parameters to exactly recommend alternate options to the branded medication a buyer calls for. It considers nuances equivalent to whether or not the drugs is sugar-coated whether it is for a younger affected person, the place it’s manufactured, and whether or not the plant is GMP-certified, amongst others. The startup additionally has a chatbot to handle some consumer queries shortly.
Way more is on the roadmap. The corporate plans to develop an AI-based system that customizes conversations based mostly on prospects’ conduct and former interactions with generic alternate options. It’s additionally opening a Bengaluru workplace whereas dedicating at the least 20% of its capital to engineering and product improvement.
Past medicines, Truemeds is plotting to enter diagnostics by way of partnerships with nationwide pathology labs, planning to pilot lab testing companies in some tier-2 cities within the subsequent three to 4 months.
“The first mission stays the identical, which is making healthcare reasonably priced for the top consumer,” the co-founder mentioned. “It began with medicines. Now that the mannequin is getting established, we’re going to preserve scaling that. Concurrently, we additionally need to see if we will do one thing related on the diagnostics entrance, the place we may be the bottom value supplier of at the least the commonest checks.”
The startup additionally plans to extend its success heart rely by 300% — from 19 at present — over the subsequent 12 months, aiming to deepen its presence in current markets.
Earlier than this spherical, Truemeds raised $50 million and nonetheless has 30–35% of that capital within the financial institution, Nayyar mentioned.
The startup has a workforce of two,800 individuals, with 250 based mostly in its Mumbai workplace.
